Fitbit’s ECG app is slated to be available in October. The product winning a nod in both the U.S. and Europe comes about two years after Apple won a nod from FDA for an ECG app to run on its smartphone. It also comes at a time when Fitbit is in...

The company also launched an early feasibility study for the investigational device, dubbed Intrepid.

San Ramon, CA-based BioVentrix is developing a hybrid transcatheter device for left ventricular remodeling after a heart attack. The pivotal trial for the device was originally scheduled to be completed by the end of the year. Now the trial is on...

Abbott Laboratories is making another go of it with reabsorbable stents. The Abbott Park, IL-based company is starting the launch of the LIFE-BTK clinical trial to evaluate the Esprit below-the-knee drug-eluting resorbable scaffold

CardioMech is developing a transcatheter system that it hopes could be used as an alternative to open-heart cardiac surgery to reduce or eliminate mitral regurgitation.

The post-market registry is evaluating the Auryon Atherectomy System. AngioDynamics inherited the device when it acquired Eximo Medical in October of last year.

The Danvers, MA-based company's EUA is specifically related to the Impella heart pumps providing left ventricular unloading and support COVID-19 patients.

Despite the procedure volume impact from COVID-19, Boston Scientific shared an upbeat outlook on the rest of the year.

Edwards Lifesciences management acknowledged some recently cancelled cases due to COVID-19 resurgence, but still offers confident outlook for the back half of the year.